IRIS
MUTTI, LUCIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.099
AS - Asia 2.189
EU - Europa 1.428
SA - Sud America 328
AF - Africa 41
AN - Antartide 1
Totale 7.086
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.027
SG - Singapore 1.064
RU - Federazione Russa 619
CN - Cina 393
HK - Hong Kong 374
IE - Irlanda 332
BR - Brasile 273
VN - Vietnam 195
IT - Italia 157
FR - Francia 120
GB - Regno Unito 50
DE - Germania 45
CA - Canada 41
IN - India 31
FI - Finlandia 28
BD - Bangladesh 21
MX - Messico 20
JP - Giappone 19
AR - Argentina 16
TR - Turchia 16
SE - Svezia 14
ES - Italia 13
IQ - Iraq 13
ZA - Sudafrica 13
NL - Olanda 11
PL - Polonia 10
CO - Colombia 8
UZ - Uzbekistan 8
PK - Pakistan 7
SA - Arabia Saudita 7
VE - Venezuela 7
BE - Belgio 6
EC - Ecuador 6
ID - Indonesia 6
MA - Marocco 6
PY - Paraguay 6
UA - Ucraina 6
AE - Emirati Arabi Uniti 5
LT - Lituania 5
MY - Malesia 5
AZ - Azerbaigian 4
KE - Kenya 4
CL - Cile 3
EG - Egitto 3
JO - Giordania 3
KR - Corea 3
OM - Oman 3
PE - Perù 3
SN - Senegal 3
TN - Tunisia 3
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HN - Honduras 2
KG - Kirghizistan 2
NG - Nigeria 2
PH - Filippine 2
SR - Suriname 2
UY - Uruguay 2
ZW - Zimbabwe 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
AT - Austria 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
CU - Cuba 1
DZ - Algeria 1
GP - Guadalupe 1
GY - Guiana 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
NI - Nicaragua 1
NP - Nepal 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
RW - Ruanda 1
SI - Slovenia 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 7.086
Salva come PNG Salva come JPEG
Città #
San Jose 776
Singapore 579
Dallas 392
Hong Kong 363
Dublin 331
Ashburn 325
Santa Clara 320
Council Bluffs 242
Boardman 192
The Dalles 174
Moscow 140
Lauterbourg 110
Hefei 83
Assago 76
Beijing 72
Los Angeles 64
New York 64
Ho Chi Minh City 55
Hanoi 51
Brooklyn 25
São Paulo 22
Chicago 20
Tokyo 19
Da Nang 17
Falkenstein 16
Orem 16
Munich 14
Stockholm 14
Columbus 13
Helsinki 13
Montreal 13
Chennai 12
Boston 11
Lappeenranta 11
San Francisco 11
L’Aquila 10
Phoenix 10
Rome 10
Denver 9
London 9
Manchester 9
Mexico City 9
Seattle 9
Warsaw 9
Johannesburg 8
Ninh Bình 8
Rio de Janeiro 8
Amsterdam 7
Atlanta 7
Tashkent 7
Erbil 6
Frankfurt am Main 6
Milan 6
Ankara 5
Calgary 5
Charlotte 5
Florence 5
Guangzhou 5
Poplar 5
Secaucus 5
Shanghai 5
Washington 5
Baku 4
Bari 4
Brussels 4
Bắc Ninh 4
Curitiba 4
Dhaka 4
Haiphong 4
Houston 4
Karachi 4
Manhuaçu 4
Mumbai 4
Nairobi 4
Ottawa 4
Paris 4
Pittsburgh 4
Querétaro 4
Recife 4
Riyadh 4
Toronto 4
Turku 4
Amman 3
Baghdad 3
Belo Horizonte 3
Biella 3
Biên Hòa 3
Brasília 3
Bến Tre 3
Campinas 3
Clifton 3
Dakar 3
Goiânia 3
Hangzhou 3
Hải Dương 3
Kansas City 3
Krasnodar 3
Milwaukee 3
New Delhi 3
Nuremberg 3
Totale 4.982
Salva come PNG Salva come JPEG
Nome #
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 97
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma 92
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma 92
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology 92
{CONFIRM} trial: what is the real efficacy of second-line immunotherapy in mesothelioma? 91
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations 83
TNF-α determination in serum and pleural effusion in patients with lung cancer 82
European Respiratory Society Guideline on various aspects of quality in lung cancer care 82
The function and clinical implication of YTHDF1 in the human system development and cancer 79
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review 79
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma 74
P53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification 74
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point? 74
HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy 73
Neuro–Immune Interactions in Severe COVID-19 Infection 72
Abemaciclib for malignant pleural mesothelioma 70
Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD 68
Association of SV40 with human tumours 66
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo 66
Chemoprevention of asbestos-linked cancers: A systematic review 66
Genetic susceptibility to malignant mesothelioma and exposure to asbestos: The influence of the familial factor 66
Over-Expression of Long Non-Coding RNA-AC099850.3 Correlates With Tumor Progression and Poor Prognosis in Lung Adenocarcinoma 65
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation 65
The function and clinical implication of circular RNAs in lung cancer 65
Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma 64
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy 64
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial 61
Preclinical Demonstrations of Synergistic Active Nutrient/Drug (and) Combination as a Potential Treatment for Malignant Pleural Mesothelioma 61
Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro 60
Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma 60
Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia 59
CDK4, CDK6/cyclin‐d1 complex inhibition and radiotherapy for cancer control: A role for autophagy 58
Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group 58
Simian virus 40 and malignant mesothelioma (Review) 57
Erionite and asbestos differently cause transformation of human mesothelial cells 57
A molecular epidemiology case control study on pleural malignant mesothelioma 57
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 57
Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2-dependent T-type Ca2+ channel opening 56
What can independent research for mesothelioma achieve to treat this orphan disease? 56
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma 56
Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies? 55
In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors 55
Editorial: Prognostic factors in non-small cell lung cancer 55
When Ron met Tam in mesothelioma: All druggable for one, and one drug for all? 55
Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor 55
Recurrent chromosome 6 abnormalities in malignant mesothelioma 54
Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma 54
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people 54
Erratum: Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma (Genes, Chromosomes and Cancer (2000) 29 (173-179)) 54
Comparison between plasma and serum osteopontin levels: Usefulness in diagnosis of epithelial malignant pleural mesothelioma 53
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma 53
SV40 and human brain tumors [2] 52
Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress 52
Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis 52
Will antiangiogenic agents be a future for mesothelioma therapy? 51
Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer 51
Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications 51
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma 50
Targeting hypoxic response for cancer therapy 50
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 50
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts 50
Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution 50
Variations in aspecific bronchial reactivity elicited by methacholine in chronic bronchitis patients treated with doxofylline. Double blind cross-over study versus theophylline slow-release 49
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer 49
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism 49
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to Gefitinib 49
New standard for assessing asbestos exposure and its consequences? 49
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients 49
New agents in the management of advanced mesothelioma 49
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma 48
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients 48
In arrayed ranks array technology in the study of mesothelioma steven 47
BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment 47
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 47
Taurolidine and oxidative stress: A rationale for local treatment of mesothelioma 47
Expression of glycoprotein 90K in human malignant pleural mesothelioma: Correlation with patient survival 47
Evaluation of a series of serum mesothelin in patients with pleural Malignant Mesothelioma 46
Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase 46
Study of the combined role of asbestos and SV40 in the pathogenesis of malignant mesothelioma 46
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure 46
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo 46
Simian Virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey 46
Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas 46
Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells 46
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma 45
SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: A molecular epidemiologic case-control study 45
SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma 45
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor 44
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications 43
Translational therapies for malignant pleural mesothelioma 43
Malignant mesothelioma as both a challenge and an opportunity 43
Scientific Advances and New Frontiers in Mesothelioma Therapeutics 43
Expression status of candidate genes in mesothelioma tissues and cell lines 43
Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases 42
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma 42
Establishment of four new mesothelioma cell lines: Characterization by ultrastructural and immunophenotypic analysis 42
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 42
Gamma/delta T-lymphocytes in advanced pulmonary asbestosis 41
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma 41
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 41
Totale 5.657
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.316
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.316
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023395 0 0 0 0 0 0 0 53 327 0 4 11
2023/2024354 7 13 18 55 19 141 0 7 3 26 24 41
2024/20252.387 176 28 153 30 215 266 240 109 658 119 235 158
2025/20264.100 172 455 333 396 317 237 933 154 368 360 351 24
Totale 7.236